Mayo Clinic and Thermo Fisher Collaborate on Multi-Omics Initiative to Detect Disease Early

Launch of Precure, LLC

A new initiative aims to harness multi-omics data to enhance disease detection and transform patient care.

Located in Rochester, Minnesota, Mayo Clinic has partnered with Thermo Fisher Scientific to initiate Precure, LLC. This venture seeks to reimagine how the healthcare sector perceives the biological transitions from wellness to illness. By harnessing extensive biological datasets, Precure aims to illuminate early signals of disease.

The Mission of Precure, LLC

The primary goal of Precure is to assemble one of the largest biomedical datasets worldwide, utilizing a multi-omics approach that integrates proteomic, genomic, and longitudinal clinical data. By accumulating information from one million biospecimens over several years, researchers aim to uncover early biological indicators that can predate clinical symptoms.

Recognizing that many diseases develop well before manifesting obvious symptoms, Precure seeks to bridge the gap between molecular changes and clinical data. This connection can potentially lead to earlier diagnoses and personalized treatment plans for conditions like cancer, cardiovascular disease, and neurodegenerative disorders.

Data Integration and Technological Advancements

Precure's strategy focuses heavily on the integration of molecular and clinical data. The vast datasets will leverage Mayo Clinic's extensive expertise in clinical data collection combined with Thermo Fisher's advanced scientific technologies. This partnership aims to ensure the highest level of data standardization and reliability.

Advanced artificial intelligence and data analytics are crucial to the venture's goals. By identifying patterns within complex datasets, the collaboration can convert raw data into meaningful insights. Dr. Gianrico Farrugia, president and CEO of Mayo Clinic, emphasizes that harnessing multi-omics data not only enables earlier disease detection but opens doors to targeted treatments and improved patient outcomes.

Expertise and Contributions

Both Mayo Clinic and Thermo Fisher bring unique strengths to this partnership. Mayo Clinic contributes its renowned clinical acumen, a vast library of de-identified clinical data, and years of research experience. In contrast, Thermo Fisher enhances the initiative with its recognized proficiency in proteomics and pioneering technologies, such as the Olink™ Explore HT platform and high-resolution mass spectrometry solutions.

“This collaboration has the potential to transform how multi-omics data is used to benefit human health,” says Marc Casper, Chairman and CEO of Thermo Fisher Scientific. “Together, we aim to create pathways for earlier detection of diseases, accelerate drug development processes, and enable precision therapies at an unprecedented scale.”

Complementary Scientific Initiatives

Precure operates in tandem with Mayo Clinic's Precure Research, an investigator-led project also focused on understanding the biological transitions toward disease. While Precure Research delves into the science of early disease signals, Precure, LLC provides the infrastructure and scale necessary to generate vast molecular data, translating these findings into diagnostics and therapeutic options.

The combined capabilities aim to facilitate breakthroughs in patient care and foster collaborative research efforts across the healthcare ecosystem.

Reinvestment into Healthcare

Mayo Clinic's establishment of Precure, LLC aligns with its mission to advance patient care through continuous innovation. Any financial returns generated by this venture will be reinvested into Mayo Clinic's nonprofit mission, concentrating on patient care, research, and educational initiatives.

For more information on Precure, visit mayo.edu/research/precure.

About the Partners

Precure, LLC is directed towards generating large-scale molecular data linked with extensive longitudinal clinical insights. Its objective combines external collaborations with discovery efforts focused on diseases to pioneer advancements in diagnostics and therapeutics.

Mayo Clinic is a nonprofit organization devoted to innovation in clinical practice and research. They offer expert care and answers to all who seek healing. More details can be found on the Mayo Clinic News Network.

Thermo Fisher Scientific leads the sector in providing essential scientific tools and services, dedicating its efforts towards enhancing the health and safety of all. Visit www.thermofisher.com for further information.

For media inquiries, contact:
Tom Millikin, Mayo Clinic Communications, [email protected]
Jodie Wertheim, Thermo Fisher Scientific, [email protected]

The details provided in this piece reflect the priority of early disease detection and increased efficiency in patient care driven by innovation and collaboration in the healthcare sector.